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Abstract
Background: Activation of adenosine A1 receptors has neuroprotective effects in animal stroke models. Adenosine
levels are regulated by nucleoside transporters. In vitro studies showed that neuron-specific expression of human
equilibrative nucleoside transporter 1 (hENT1) decreases extracellular adenosine levels and adenosine A1 receptor
activity. In this study, we tested the effect of hENT1 expression on cortical infarct size following intracerebral
injection of the vasoconstrictor endothelin-1 (ET-1) or saline.
Methods: Mice underwent stereotaxic intracortical injection of ET-1 (1 μl; 400 pmol) or saline (1 μl). Some mice
received the adenosine receptor antagonist caffeine (25 mg/kg, intraperitoneal) 30 minutes prior to ET-1. Perfusion
and T2-weighted magnetic resonance imaging (MRI) were used to measure cerebral blood flow (CBF) and
subsequent infarct size, respectively.
Results: ET-1 reduced CBF at the injection site to 7.3 ± 1.3% (n = 12) in hENT1 transgenic (Tg) and 12.5 ± 2.0%
(n = 13) in wild type (Wt) mice. At 48 hours following ET-1 injection, CBF was partially restored to 35.8 ± 4.5% in
Tg and to 45.2 ± 6.3% in Wt mice; infarct sizes were significantly greater in Tg (9 ± 1.1 mm
3) than Wt (5.4 ± 0.8
mm
3) mice. Saline-treated Tg and Wt mice had modest decreases in CBF and infarcts were less than 1 mm
3. For
mice treated with caffeine, CBF values and infarct sizes were not significantly different between Tg and Wt mice.
Conclusions: ET-1 produced greater ischemic injury in hENT1 Tg than in Wt mice. This genotype difference was
not observed in mice that had received caffeine. These data indicate that hENT1 Tg mice have reduced ischemia-
evoked increases in adenosine receptor activity compared to Wt mice.
Keywords: Endothelin 1, Human Equilibrative Nucleoside Transporter 1, CD1, Mouse, Magnetic Resonance Imaging,
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Background
Stroke is a leading cause of death and disabilities in
developed countries. During stroke, a rapid depletion of
ATP, dysregulation of ion channels and pumps, collapse
of ion homeostasis, release of excitotoxic neurotransmit-
ters, and intracellular calcium overload triggers a series
of enzymatic cascades that result in neuronal death
[1,2]. Unfortunately, with the exception of tissue
plasminogen activator, there are as yet no clear evi-
dence-based strategies for treatment [2].
Adenosine is a neuromodulator that acts through a
family of metabotropic receptors. Activation of adeno-
sine A1 receptors, which are widely distributed in brain,
has neuroprotective effects. In contrast, activation of
A2A receptors, which are most abundant in basal
ganglia, can promote cell injury [3]. Adenosine can be
formed extracellularly from catabolism of ATP by a cas-
cade of ecto-nucleotidases [4], or can be formed intra-
cellularly from ATP consumed in energy requiring
processes followed by hydrolysis of AMP by cytosolic
5’-nucleotidases. Equilibrative nucleoside transporters
(ENT) mediate cellular influx or efflux of adenosine and
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gradients [5]. During pathophysiological events such as
stroke or brain trauma, adenosine levels can increase up
to 100-fold; the origin of this adenosine has been
addressed in vitro using pharmacological tools but little
information from in vivo studies is available [6,7].
Genetically altered mice can be used to investigate
ischemic injury at the molecular level [8]. One method
for producing a cerebral infarct in rodents is intracereb-
ral injection of the vasoconstrictor peptide endothelin-1
(ET-1) [9-11]. Compared to other methods for produ-
cing stroke, such as distal middle cerebral artery occlu-
sion or thromboembolic models, ET-1 induced focal
lesions are relatively simple and reproducible [12].
Moreover, ET-1 is not directly neurotoxic but produces
a temporary reduction in blood flow for several hours at
the injection site [13,14].
In the present study ET-1 or saline was administered
by intracortical injection to wild type (Wt) and trans-
genic (Tg) mice with neuron-specific expression of
human ENT1 (hENT1) [15]. Local changes in cerebral
blood flow and development of a cerebral infarct were
monitored by magnetic resonance imaging (MRI) to test
whether ENT1 over-expression affected stroke injury in
a brain region expressing adenosine A1 receptors. The
role of adenosine receptors in responses of Wt and Tg
mice to ET-1 were examined with the antagonist
caffeine.
Methods
Mice
CD1 mice with neuronal expression of hENT1 were
generated as previously described [15]. To compare Tg
to Wt mice, heterozygous Tg male mice were bred to
Wt females and 8-10 week old (35-40 g) heterozygous
Tg and Wt male littermates were used. All procedures
and all outcome analyses were performed by individuals
who were blinded to the genotype of the mice. All pro-
cedures with animals were approved by the University
of Manitoba Animal Protocol Management and Review
Committee.
Surgical procedure
Mice were anesthetized initially with 5% isoflurane for
i n d u c t i o nt h e nm a i n t a i n e dw i t h1 . 5 - 2 %i s o f l u r a n ei n
30% oxygen and 70% nitrous oxide. Rectal temperature
was kept between 37-37.5°C through a thermal pad dur-
ing the procedure and was maintained by a heating
lamp during the recovery. Mice were placed in a stereo-
taxic apparatus. Following a midline incision to the
scalp, a small burr hole was placed in the right hemi-
sphere. A 5 μl Hamilton syringe was used to inject 1 μg
ET-1 (Sigma-Aldrich Canada, Oakville, ON, Canada)
(400 pmol in 1 μl of saline) or saline (1 μl) to the cortex
in 5 minutes. One group of mice received caffeine
(25 mg/kg) by intraperitoneal (i.p.) injection 30 minutes
prior to intracortical injection of ET-1. The stereotaxic
coordinates were determined from a mouse atlas [16]
and were 1.0 mm anterior, and 1.0 mm lateral, to
bregma and 1.2 mm below the pia. The needle was left
in situ for 5 minutes to prevent back flow of ET-1 or
saline before being slowly withdrawn. The hole was
covered by bone wax and the incision was sutured.
Magnetic resonance imaging
Mice were examined with perfusion-weighted MRI at 4
and 48 hours post-injection to confirm decreased cere-
bral blood flow (CBF). In addition, they were examined
with T2 weighted MRI at 48 hours to determine infarct
size. A Bruker Biospec 7 T/21 cm spectrometer (Bruker
BioSpin, Karlsruhe, Germany) with a quadrature volume
coil (National Research Council, Winnipeg, MB,
Canada) 2.5 cm in diameter was used for MRI. Mice
were anesthetized with 1.5 to 2% isoflurane in 30% oxy-
g e na n d7 0 %n i t r o u so x i d ea n dp l a c e di na na n i m a l
holder with a thermal pad keeping body temperature at
37 to 37.5°C. The respiration rate was monitored using
a pneumatic pillow connected to a respiratory monitor
(Small Animal Instruments Inc., Stony Brook, NY,
USA). Relative CBF was measured using an adiabatic
spin labeling sequence with a 36 -echo HASTE readout
following a 400 ms post tagging delay at 1 mm slice
thickness and in-plane resolution of 234 μm. Slices were
obtained at the plane of the injection site and at bregma
for CBF measurement.
For T2 weighted images a multi-slice 8-echo RARE
method with effective echo time TE = 80 ms and slice
thickness 0.5 mm and 100 μm in-plane resolution was
used. A total of 12 continuous slices were obtained with
1 mm inter-slice spacing in two 6-slice sets.
MRI analysis was performed using Marevisi 7.2
analysis software (National Research Council, Winnipeg,
M B ,C a n a d a ) .T h ed e p t ho fi schemia was assessed by
measuring relative blood flow within a 0.9 cm diameter
circular area centered on the injection site. Those values
were expressed as a percentage of pre-injection CBF
values. Ischemia was defined as a decrease in CBF to
less than 20% of pre-injection CBF [18]. Infarct size was
obtained by measuring the area of hyperintense pixels in
T2 weighted images, multiplying by the slice thickness
and summing to obtain the infarct volume for each
animal.
Statistical analysis
The first study comparing outcomes of saline and ET-1
injections to Wt and Tg littermates was analyzed by
two-way analysis of variance (ANOVA). In these ANO-
VAs, ipsilateral and contralateral CBF and ipsilateral
Soylu et al. Experimental & Translational Stroke Medicine 2012, 4:4
http://www.etsmjournal.com/content/4/1/4
Page 2 of 8infarct size were outcome variables and genotype (Wt
or Tg) and drug (saline or ET-1) groups were treated as
between-subject factors. For ipsilateral and contralateral
CBF, assessments at 4 and 48 hours were examined for
group differences. Follow-up pair-wise comparisons
with Bonferroni adjustment of type I error were also
conducted to examine differences across genotype and
drug groups. The second study comparing outcomes of
Wt and Tg littermates following i.p. injection of caffeine
30 minutes prior to intracortical injection of ET-1 was
analyzed by two-way ANOVAs (CBF) or t-test (infarct
size). No animals were excluded from analysis and no
mortality occurred. All p-values were two-sided, and
significance was set at a value of 0.05 for multiple com-
parisons. Statistical analyses were performed using SAS
Version 9 (SAS Institute Inc, Cary, NC) or GraphPad
Prism Version 5 (GraphPad Software Inc., LaJolla, CA).
Results
ET-1 and saline significantly decreased CBF at 4 hours
post-injection
Perfusion weighted MRI was performed at 4 and 48
hours following intra-cortical injections of ET-1 or
saline and representative pseudocolor images are shown
in Figure 1A. Compared to pre-injection values, ipsilat-
eral CBF (± SEM) was decreased following injection of
ET-1 or saline (Figure 2). Analysis of ipsilateral CBF at
4 hours indicated a significant effect of genotype
(F(1,29) = 27.4, p < 0.01), a significant drug effect
(F(1,29) = 126.1, p < 0.001) and a significant genotype
by drug interaction (F(1,29) = 14.8, p < 0.01). Follow-up
pair-wise comparisons indicated that ET-1 produced a
greater decrease in CBF than saline, and a genotype
difference was observed in mice injected with saline
(p < 0.05) but not in mice injected with ET-1. Analysis
of contralateral CBF at 4 hours also indicated a signifi-
cant effect of genotype (F(1,29) = 7.01, p < 0.05) and a
significant drug effect (F(1,29) = 10.6, p < 0.01) as ET-1
produced a greater decrease in contralateral CBF in
hENT1 Tg mice than in Wt littermates (Figure 2, inset).
CBF decreases persist 48 hours following injection of ET-1
but not saline
At 48 hours after injection of ET-1 the decrease in
ipsilateral CBF was still evident whereas at 48 hours
after injection of saline CBF was restored to pre-
injection levels (Figure 3). Two-way ANOVA revealed a
statistically significant effect of drug (F (1, 29) = 50.9,
p < 0.001), with a significant difference between ET-1
and saline injected mice (p < 0.05). No significant effect
of genotype was detected. The small decreases in con-
tralateral CBF that were observed 4 hours after ET-1
injection were resolved by 48 hours (Figure 3, inset).
Intra-cortical ET-1 injections produce a greater infarct size
in hENT1 Tg than Wt mice
T2 weighted MRI was performed at 48 hours following
intra-cortical injections of ET-1 or saline and represen-
tative images are shown in Figure 1B. Saline injections
produced measurable infarcts (0.3 ± 0.1 mm
3 for Wt and
0 . 7±0 . 4m m
3 for hENT1 Tg) that were smaller than
infarcts resulting from ET-1 injections (5.4 ± 0.8 mm
3 for
Wt and 9.0 ± 1.1 mm
3 for hENT1 Tg) (Figure 4). Two-
way ANOVA indicated a significant drug effect (F(1, 27)
= 22.3, p < 0.001). Pair-wise comparisons indicated no
difference between Wt and hENT1 Tg mice injected with
saline but a significantly larger infarct in hENT1 Tg, rela-
tive to Wt mice, following ET-1 injection (p < 0.05).
Caffeine abolishes genotype differences in response to
ET-1 injections
The severe and long-lasting decrease in CBF following
intracortical injection of ET-1 was also observed in mice
pre-treated with caffeine. At 4 hours following ET-1
injection, ipsilateral CBF was reduced below the
ischemic threshold of 20% in both Wt and Tg mice
(Figure 5A). At 48 hours after ET-1 injection, ipsilateral
CBF was restored to approximately 50% of pre-ischemic
levels, in both genotypes (Figure 5B). At 4 hours after
ET-1 injection, contralateral CBF was reduced to 77%
and 87% in Tg and Wt mice, respectively, and was
Figure 1 Perfusion weighted and T2 weighted MR images after
cortical injection of 1 μl ET-1. A. Representative perfusion
weighted MR images obtained from a Wt mouse before injection
(pre; left) of ET-1 (400 pmol; 1 μl), and at 4 hours (4 h; middle) and
48 hours (2 d; right) post-ET-1 injection. Pseudocolor scale bar
shows average cerebral blood flow (CBF) pre-injection (Avg) and
ischemic threshold, set at 20% of pre-injection average (20%). B.
Representative T2 weighted MR images obtained from a Wt mouse
48 hours post-injection of ET-1. In each panel, the number at the
upper left shows the position relative to bregma. The arrow shows
the injection site at +1.0 mm anterior to bregma.
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following ET-1 injection. Ischemic infarct sizes, mea-
s u r e da t4 8h o u r s ,w e r e6 . 2±1a n d6 . 7±1m m
3,a n d
were not significantly different between Tg and Wt
mice (Figure 5C).
Discussion
The main finding of this study was that hENT1 Tg mice
showed similar decreases in CBF, but had greater infarct
sizes following ET-1 injection than Wt mice. Systemic
pretreatment with the adenosine receptor antagonist
caffeine abolished the genotype differences in infarct
size, implicating differences in endogenous adenosine
and adenosine receptor activity between Wt and hENT1
Tg mice.
ET-1 has been used previously to produce experi-
mental strokes in rats [9,10,13] but mixed success has
been reported with mice [8,11,17] leading some to
conclude that ET-1 is not useful for mouse stroke
models [8,12]. We found a significant CBF response to
ET-1 injection that persisted for at least 48 hours ipsi-
laterally and led to cortical infarcts greater than 5
mm
3. Using laser Doppler to measure CBF changes in
mice after intracortical ET-1 injection, Wang et al.
(2007) reported an 80% drop in CBF following 1 μg
ET-1 injection, similar to the 90% drop in CBF at 4
hours that we report, and cortical infarcts of approxi-
mately 12 mm
3 [ 1 1 ] .T h e r e f o r e ,w ec o n c l u d et h a tE T - 1
is an effective method for establishing a cortical infarct
in mice.
Figure 2 Cerebral blood flow (CBF) is decreased 4 hours after intra-cortical injection of endothelin-1 (ET-1) or saline.C B Fw a s
quantitated, relative to pre-injection set at 100%, in a 0.9 cm diameter circular region-of-interest centered on the injection site. Two-way ANOVA
of ipsilateral CBF indicated a significant effect of genotype (F(1, 29) = 27.4, p < 0.01), a significant drug effect (F(1, 29) = 136.1, p < 0.001) and a
significant genotype by drug interaction (F(1, 29) = 14.8, p < 0.01). Bonferroni post-tests indicated a significant difference (p < 0.05) between Wt
and Tg mice injected with saline but not between Wt and Tg mice injected with ET-1. Inset ET-1, but not saline, injections were associated with
decreased contralateral CBF. Two-way ANOVA of contralateral CBF at 4 hours also indicated a significant effect of genotype (F(1, 29) = 7.01, p <
0.05) and a significant drug effect (F(1, 29) = 10.6, p < 0.01). Bonferroni post-tests indicated that ET-1 produced a significantly greater decrease in
contralateral CBF in Tg mice than in Wt littermates (p < 0.05). Data are means ± SEM, n = 12 Tg ET-1, 13 Wt ET-1, 4 Tg saline and 4 Wt saline.
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found batch to batch variability in the stroke sizes
produced by ET-1 injections. Thus, while the genotype
difference in stroke size that we report here was also
seen in pilot experiments, the average infarct sizes were
different with each ET-1 preparation.
Previously, it has been reported that a decrease in CBF
to 20% of control levels is required for stroke injury
[18]. In this study, ET-1 administration produced an
effect on CBF that equaled or surpassed this level of
ischemia. The duration of the ischemic episode was not
determined specifically, but was at least 4 hours. Using
saline as a volume control, we found that mechanical or
traumatic factors associated with injections produced
decreases in CBF in ipsilateral cortex that persisted for 4
hours; however, these injections produced small infarcts
that amounted to approximately 10% of the infarct sizes
observed with injections of an equal volume of ET-1.
From our data it appears that saline administration pro-
duced small cerebral infarcts without decreasing CBF
below 20%. As CBF was determined using a circle of 0.9
Figure 3 Decreases in ipsilateral cerebral blood flow (CBF) persist for 48 hours after intra-cortical injection of endothelin-1 (ET-1). CBF
was quantitated in a 0.9 cm diameter circular region-of-interest centered on the injection site. Two-way ANOVA revealed a statistically significant
effect of drug (F (1, 29) = 50.9, p < 0.001) and Bonferroni post-tests revealed a significant effect of ET-1 for both Wt and Tg mice (p < 0.05). No
significant differences between Tg and Wt were detected. Inset Contralateral CBF was restored to control levels 48 hours after injection of either
saline or ET-1. Data are means ± SEM, n = 12 Tg ET-1, 13 Wt ET-1, 4 Tg saline and 4 Wt saline.
Figure 4 Ischemic injury from ET-1 injection is greater in
hENT1 Tg mice compared to Wt littermates. Ischemic infarct size
was determined from T2 weighted MRI at 48 hours post injection of
either saline or ET-1. Two-way ANOVA indicated a significant drug
effect (F(1, 27) = 22.3, p < 0.001). Bonferroni post-tests indicated no
difference between Wt and hENT1 Tg mice injected with saline but
a significantly larger infarct in hENT1 Tg, relative to Wt mice,
following ET-1 injection (p < 0.05). Data are means ± SEM, n = 12
Tg ET-1, 13 Wt ET-1, 4 Tg saline and 4 Wt saline.
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infarct sizes are likely associated with ischemic areas, of
CBF below 20%, that are smaller than the 0.9 cm dia-
meter circle. It is also possible that a more severe
decrease in CBF occurred but resolved within 4 hours of
saline injection.
Both saline and ET-1 produced measurable decreases
in contralateral CBF; however, these decreases were
modest and not of a magnitude associated with cerebral
infarct. In studies using unilateral stroke models, it is
sometimes assumed that the contralateral hemisphere is
spared from CBF changes and that it can serve as an
internal control [19]. However, contralateral cell death
has been observed after middle cerebral and common
carotid artery occlusion to ipsilateral hemisphere
[19,20]. Furthermore, contralateral changes in hypoxia
induced factor-1a, P-Akt, P-ERK1/2 and the proinflam-
matory cytokines IL-b,T N F - a and TNF-b have been
observed in the absence of histopathological evidence
for ischemic injury [21]. These results all indicate that a
central autoregulatory system can affect CBF responses
in brain regions beyond the immediate site of injury.
Adenosine is an important neuromodulator in many
neurological events including ischemia, hypoxia and sei-
zures [22]. During ischemic conditions, increases in ade-
nosine levels of up to 100-fold have been measured
[6,7]. This adenosine may be derived from neurons,
astrocytes, or other cells that release ATP, which is then
metabolized extracellularly to adenosine by ecto-nucleo-
tidases [4]. Alternatively, adenosine can be released from
cells via ENT-mediated efflux, a process that has been
documented in neuronal cell cultures [23,24]. Other
mechanisms of adenosine release, including vesicular
release from neurons or astrocytes have been proposed
[25-27]. In the present study, ET-1 was injected directly
into a brain region that is rich in adenosine A1 receptors
and expresses few A2A receptors. This injection pro-
duced a similar decrease in CBF in Wt and hENT1 Tg
mice at the injection site yet the resulting cerebral
infarct volume was significantly greater in hENT1 Tg
mice relative to Wt. This indicates that hENT1 Tg mice
had reduced endogenous neuroprotection or enhanced
neurotoxicity, relative to Wt mice. Using hippocampal
slice preparations, we recently reported that slices from
hENT1 Tg mice show increased adenosine uptake and
reduced adenosine receptor activity in response to
h y p o x i co ri s c h e m i cc o n d i t i o n st h a ns l i c e sf r o mW t
mice [28], consistent with the results of the present
study. Because the brain region targeted by ET-1 injec-
tions expresses A1 receptors at a much higher density
than A2A receptors [29], it is likely that the effect of
hENT1 expression to increase stroke injury is a direct
Figure 5 Caffeine pre-treatment abolished the genotype
difference in severity of ET-1 induced cerebral infarcts. Mice
were injected with the adenosine receptor antagonist caffeine (25
mg/kg, i.p.) 30 minutes prior to intracerebral injection of ET-1. A.
Ipsilateral CBF was decreased to less than 20% in both Tg and Wt
mice; contralateral CBF was decreased by less than 20% at 4 hours
post ET-1 injection. B. At 48 hours post ET-1 injection, partial
recovery of ipsilateral CBF and full recovery of contralateral CBF was
evident. C. Ischemic infarct size, determined 48 hours after ET-1
injection was similar in Tg and Wt mice. Data are means ± SEM; n =
10 Tg, 10 Wt mice.
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adenosine and decreased A1 receptor activation, relative
to Wt mice [28]. A recent study using ENT1 null mice
reported decreased ischemia-reperfusion injury to heart
relative to Wt controls [30], which is consistent with the
increased infact size in ENT1 over-expressing mice
reported here.
Caffeine is a non-selective adenosine receptor
antagonist with approximate Ki values of 12 and 2.4
μMf o rA 1 and A2A receptors [31]. Caffeine was used
for this study because of its clinical significance as a
commonly consumed psychoactive drug. Furthermore,
caffeine has been used previously in Wt and hENT1
Tg mice and found to affect motor activity and etha-
nol-induced motor in-coordination [15,32]. The phar-
macokinetics of caffeine has been examined in mice
and a half-life of 25 minutes was reported [33]. There-
fore, 30 minutes after caffeine treatment, at the time of
ET-1 injection, caffeine levels are expected to still be
in a range at which pharmacological effects have been
observed in previous studies [15]. After caffeine admin-
istration, ET-1 no longer produced a significantly
greater ischemic injury in Tg mice relative to Wt mice.
These data further indicate that adenosine receptor
activity is important for the difference in stroke injury
size between Tg and Wt mice. The apparent lack of
effect of caffeine in Tg mice may indicate that adeno-
sine A1 receptor activity was minimal in the penum-
bral region in these mice, as a direct consequence of
the increased neuronal uptake of adenosine mediated
by functional hENT1.
Conclusions
Cortical ET-1 injection is a relatively simple and repro-
ducible technique for producing a cerebral infarct in
mice. Following ET-1 injection, Tg mice expressing
hENT1 in neurons showed a greater cerebral infarct size
than Wt mice. Caffeine treatment prior to ET-1 injec-
tion abolished this genotype difference, implicating ade-
nosine receptors in determining final infarct size. Our
results can be explained by ENT mediated influx of ade-
nosine into neurons and attenuated adenosine A1 recep-
tor activity. This indicates that, during ischemia,
n e u r o n sd on o tr e l e a s ea d e n o s i n ev i aE N T sb u ta c t i v e l y
salvage adenosine, which may be released by another
mechanism, from another cell type, or formed extracel-
lularly from released adenine nucleotides.
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